A5032089787- Pulmonary Hypertension Research and Treatments
- Cardiovascular Issues in Pregnancy
- Venous Thromboembolism Diagnosis and Management
- Cardiovascular Function and Risk Factors
- Vascular Anomalies and Treatments
- Heart Failure Treatment and Management
- Atrial Fibrillation Management and Outcomes
- Congenital Heart Disease Studies
- Liver Disease and Transplantation
- Blood Coagulation and Thrombosis Mechanisms
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Chronic Obstructive Pulmonary Disease (COPD) Research
- Cardiac Imaging and Diagnostics
- Cardiac Ischemia and Reperfusion
- Acute Myocardial Infarction Research
- Cardiac Valve Diseases and Treatments
- Liver Disease Diagnosis and Treatment
- Eosinophilic Disorders and Syndromes
- Viral Infections and Immunology Research
- Cardiac Arrhythmias and Treatments
- High Altitude and Hypoxia
- Peptidase Inhibition and Analysis
- Mitochondrial Function and Pathology
- Renin-Angiotensin System Studies
- Myeloproliferative Neoplasms: Diagnosis and Treatment
Guangdong Academy of Medical Sciences
2023-2025
Southern Medical University
2023-2025
Guangdong Provincial People's Hospital
2023-2025
Binzhou University
2025
Binzhou Medical University
2025
Fu Wai Hospital
2012-2024
Peking Union Medical College Hospital
2015-2024
Chinese Academy of Medical Sciences & Peking Union Medical College
2015-2024
Academy of Medical Sciences
2014-2023
Shanxi Medical University
2023
Current therapies for pulmonary arterial hypertension have been adopted on the basis of short-term trials with exercise capacity as primary end point. We assessed efficacy macitentan, a new dual endothelin-receptor antagonist, using point morbidity and mortality in long-term trial.We randomly assigned patients symptomatic to receive placebo once daily, macitentan at once-daily dose 3 mg, or 10 mg. Stable use oral inhaled therapy hypertension, other than antagonists, was allowed study entry....
Riociguat, a soluble guanylate cyclase stimulator, has been shown in phase 2 trial to be beneficial the treatment of pulmonary arterial hypertension.In this 3, double-blind study, we randomly assigned 443 patients with symptomatic hypertension receive placebo, riociguat individually adjusted doses up 2.5 mg three times daily (2.5 mg-maximum group), or that were capped at 1.5 (1.5 group). The group was included for exploratory purposes, and data from analyzed descriptively. Patients who...
Pulmonary arterial hypertension (PAH) is a progressive, fatal disease. We studied 674 consecutive adult patients who were prospectively enrolled in the French PAH registry (121 incident and 553 prevalent cases). Two survival analyses performed. First, cohort of was followed for 3 yrs after study entry rates described. Then, we focused on subset with idiopathic, familial anorexigen-associated (n = 56) combined diagnosed <3 prior to 134). In patients, 1-, 2-, 3-yr 87% (95% CI 84–90), 76%...
Background— Pulmonary arterial hypertension (PAH) is a progressive, fatal disease with no cure. Parenteral and inhaled prostacyclin analogue therapies are effective for the treatment of PAH, but complicated administration requirements can limit use these in patients less severe disease. This study was designed to evaluate safety efficacy oral treprostinil diolamine as initial de novo PAH. Methods Results— Three hundred forty-nine (intent-to-treat population) not receiving endothelin receptor...
Riociguat is a soluble, guanylate cyclase stimulator, approved for pulmonary arterial hypertension. In the 12-week PATENT-1 study, riociguat was well tolerated and improved several clinically relevant end-points in patients with hypertension who were treatment naïve or had been pretreated endothelin-receptor antagonists prostanoids. The PATENT-2 open-label extension evaluated long-term safety efficacy of riociguat. Eligible from study received individually adjusted up to maximum dose 2.5 mg...
Although the phosphodiesterase type 5 inhibitors sildenafil and tadalafil have demonstrated efficacy in patients with pulmonary arterial hypertension (PAH), monotherapy these agents has not been conclusively shown to reduce clinical worsening events.To evaluate safety of inhibitor vardenafil Chinese PAH.In a randomized, double-blind, placebo-controlled study, 66 PAH were randomized 2:1 (5 mg once daily for 4 wk then twice daily; n = 44) or placebo (n 22) 12 weeks. Patients completing this...
We sought to investigate the characteristics, survival and risk factors for mortality in Chinese patients with connective tissue disease (CTD)-associated pulmonary arterial hypertension (APAH) modern therapy era. 129 consecutive adult who visited one of three referral centres China a diagnosis CTD-APAH confirmed by right heart catheterisation during previous 5 years were enrolled. The end-point was all-cause death or data censoring. Systemic lupus erythematosus most common underlying CTD...
Mitotic fission is increased in pulmonary arterial hypertension (PAH), a hyperproliferative, apoptosis-resistant disease. The mediator dynamin-related protein 1 (Drp1) must complex with adaptor proteins to cause fission. Drp1-induced has been therapeutically targeted experimental PAH. Here, we examine the role of 2 recently discovered, poorly understood Drp1 adapter proteins, mitochondrial dynamics 49 and 51 kDa (MiD49 MiD51), normal vascular cells explore their dysregulation PAH.Immunoblots...
In response to the outbreak of coronavirus disease 2019 (COVID-19) in Wuhan, China, Chinese Society Cardiology (CSC) issued this consensus statement after consulting with 125 medical experts fields cardiovascular and infectious disease. The over-arching principles laid out here are following: 1) Consider prevention control COVID-19 transmission as highest priority, including self-protection staff; 2) Patient risk assessment both infection issues. Where appropriate, preferential use...
Background Idiopathic pulmonary arterial hypertension (IPAH) is a rare disease with high heritability. Although several predisposing genes have been linked to IPAH, the genetic aetiology remains unknown for large number of IPAH cases. Methods We conducted an exome-wide gene-based burden analysis on two independent case–control studies, including total 331 cases and 10 508 controls. Functional assessments were analyse effects mutations protein biosynthesis function. Results The gene encoding...